Medexus Pharmaceuticals Balances GRAFAPEX Growth With Headwinds

Medexus Pharmaceuticals ((TSE:MDP)) has held its Q3 earnings call. Read on for the main highlights of the call.

Medexus Pharmaceuticals’ latest earnings call struck a balanced tone as management highlighted strong early traction for new launch GRAFAPEX and improving margins, even as legacy products and launch spending weighed on headline revenue and profits. Executives emphasized cash generation, reduced net debt, and new financing flexibility as key supports while the company navigates near-term earnings pressure.

GRAFAPEX Early Commercial Adoption

GRAFAPEX is gaining a foothold in the U.S. transplant market, with 32% of 180 transplant centers, or 57 institutions, having already placed orders. Reorder activity is robust, with 77% of these centers reordering, and product-level net revenue reached $8.2 million over the nine months ended Dec. 31, 2025 amid a notable rebound in patient demand in January.

GRAFAPEX Revenue and Growth Trajectory

In fiscal Q3 2026, GRAFAPEX generated $2.0 million in reported net revenue on $2.6 million of underlying patient demand, pointing to a growing usage base. Management expects product-level net revenue of $11 million to $12 million for fiscal 2026, with Q4 underlying demand forecast at roughly $3 million to $4 million as adoption broadens.

Accretive Outlook and Cash Flow Contribution

Management projects that GRAFAPEX will become accretive to quarterly operating cash flow starting in fiscal Q4 2026, marking an important inflection in the launch economics. The company has already averaged $4.3 million of cash from operations per quarter since GRAFAPEX launched, with Q3 operating cash flow rising 16.4% year over year to $7.8 million.

Improved Gross Margin Profile

Despite revenue headwinds, Medexus expanded its gross margin to 53.6% in fiscal Q3 2026 from 50.7% a year earlier, a gain of 2.9 percentage points. The improvement signals better product mix and cost efficiencies, even though absolute gross profit dollars declined during the quarter.

IXINITY Manufacturing Cost Reductions

A multi-year process improvement initiative for hemophilia drug IXINITY has delivered a 30% reduction in product-level cost of goods compared with fiscal Q1 2021. Encouraged by these savings and the margin lift they support, Medexus committed an additional $1.2 million to further enhance IXINITY manufacturing processes.

Balance Sheet and Liquidity Actions

The balance sheet continued to strengthen as net debt fell to $10.4 million at Dec. 31, 2025 from $13.2 million at March 31, 2025, reflecting debt paydown and healthy cash generation. A new senior secured credit facility cut quarterly principal repayments from $3.3 million to $0.5 million, and the company ended Q3 with $15 million of cash on hand.

Product-Specific Demand Tailwinds

Rasuvo benefited from a competitor withdrawal, driving a 17% year-over-year increase in patient unit demand in fiscal Q3 2026 and providing a welcome offset to pressure elsewhere. GRAFAPEX is also seeing particularly strong pediatric uptake, supported by its perceived fertility and toxicity advantages in this vulnerable patient group.

Capital Allocation and Shareholder Return

Medexus has leaned on its balance-sheet strength to support both growth and shareholder returns, fully repaying the remaining GRAFAPEX regulatory milestone using cash on hand. The company also launched an issuer bid and has repurchased 201,500 shares so far, signaling confidence in long-term value despite near-term volatility.

Year-over-Year Net Revenue Decline

Total net revenue fell to $25.3 million in fiscal Q3 2026 from $30.0 million a year earlier, a decline of about 15.7% that overshadowed pockets of growth. The drop was driven largely by lower Rupall sales, amid generic competition, and the return of Gleolan to its licensor, which removed its contribution from the portfolio.

Adjusted EBITDA and Profitability Pressure

Profitability metrics softened, with adjusted EBITDA slipping to $4.5 million from $5.8 million and net income dropping to $0.1 million from $0.7 million year over year. Operating income also declined to $1.7 million from $2.1 million, reflecting lost high-margin revenue and upfront investments in the GRAFAPEX commercial infrastructure.

Gross Profit Dollar Reduction

Gross profit decreased to $13.6 million in fiscal Q3 2026 from $15.2 million in the prior-year quarter, a drop of about 10.5%. This contraction shows that while Medexus is improving margin percentages, lower sales volumes and product mix changes are still weighing on total profit dollars.

Rupall Generic Competition

Rupall continues to face stiff generic competition in Canada, putting ongoing pressure on product-level net revenue after what management views as the worst of the initial shock. While the company expects some stabilization, this franchise is unlikely to return to prior levels and remains a structural headwind for overall growth.

Gleolan License Termination Impact

The termination and return of the Gleolan U.S. license removed a revenue contributor from the portfolio, further dampening year-over-year comparisons. This step contributed to lower net sales in Q3 but also allows Medexus to focus capital and commercial resources on higher-priority assets like GRAFAPEX and IXINITY.

Launch Investments Outpacing Initial GRAFAPEX Revenue

Launch spending for GRAFAPEX reached $8.5 million through Dec. 31, 2025, slightly above the $8.2 million in product-level net revenue recognized over the same period. In Q3 specifically, GRAFAPEX revenue of $2.0 million lagged behind personnel and infrastructure investments of $2.5 million, underscoring the near-term profitability drag of scaling the launch.

Cash on Hand Decline Amid Investment Phase

Cash on hand declined to $15 million at Dec. 31, 2025 from $24 million at March 31, 2025, a drop of about 37.5% linked to launch-related and other cash uses. Importantly, this drawdown occurred even as operating cash flow remained positive, highlighting management’s willingness to deploy liquidity to support long-term growth.

Quarterly Variability and Recognition Lag

Management reminded investors that reported net revenue can lag underlying patient demand because of wholesaler ordering patterns, as seen with GRAFAPEX, where Q3 demand of $2.6 million translated into $2.0 million of recognized revenue. This timing mismatch may introduce quarter-to-quarter noise and complicates short-term comparisons, even when underlying utilization is improving.

Forward-Looking Guidance and Outlook

Looking ahead, Medexus expects GRAFAPEX to generate $11 million to $12 million in fiscal 2026 product-level net revenue and to become accretive to quarterly operating cash flow in fiscal Q4 2026. Management anticipates Q4 patient demand of roughly $3 million to $4 million for GRAFAPEX, a modest rise in related SG&A, and continued leverage from margin initiatives, cash generation, and lower scheduled debt repayments.

Medexus’ earnings call painted a picture of a company in transition, absorbing hits from Rupall and Gleolan while leaning into GRAFAPEX and manufacturing-driven margin gains to fuel the next leg of growth. For investors, the key watch points will be whether GRAFAPEX hits its revenue and cash-flow targets and if the improved balance sheet can buffer the near-term earnings volatility now evident in the reported numbers.